dexamethasone

Overview

Dexamethasone is a potent synthetic glucocorticoid corticosteroid with broad anti-inflammatory, immunosuppressive, and antineoplastic properties. Structurally derived from cortisol, it binds with high affinity to the glucocorticoid receptor (GR), triggering nuclear translocation and transcriptional regulation of genes involved in inflammation, immune activation, and cellular metabolism. Its anti-inflammatory potency is approximately 25–30 times greater than hydrocortisone, making it one of the most widely deployed corticosteroids in clinical medicine. Dexamethasone acts by suppressing the production of proinflammatory cytokines such as interleukin-6 and TNF receptor superfamily signaling cascades, inhibiting NF-κB pathway activation, and modulating oxidative stress responses mediated by nuclear factor erythroid 2-related factor 2 and superoxide dismutase systems.

Beyond its classical anti-inflammatory role, dexamethasone is a cornerstone therapeutic in hematologic oncology, neuro-oncology, and ophthalmology. It is widely used in combination regimens for plasma cell dyscrasias such as multiple myeloma and systemic amyloidosis, as a prophylactic or palliative agent in central nervous system pathology, and as a reference comparator in preclinical drug discovery. Its capacity to induce muscle atrophy via FOXO1/FOXO3a-mediated upregulation of atrogin-1 (FBXO32) and MuRF-1 (TRIM63) has also made it a standard tool for modeling glucocorticoid-induced sarcopenia and skeletal muscle wasting in experimental systems.

Focus of Latest Publications

Recent publications demonstrate dexamethasone's continued central role across multiple therapeutic contexts, particularly in hematologic malignancies and as a component of novel drug delivery systems. In multiple myeloma, dexamethasone remains a cornerstone agent within combination regimens; clinical studies evaluated it as part of bortezomib-lenalidomide-dexamethasone (VRd), daratumumab-based approaches, belantamab mafodotin-containing combinations, and selinexor-based regimens (SVRD) in newly diagnosed and relapsed/refractory disease. Real-world safety analyses from the FDA Adverse Event Reporting System documented distinct adverse event profiles across regimens: dexamethasone-containing daratumumab combinations showed elevated infection signals with earlier onset, while bortezomib-based regimens demonstrated increased neurological complications. Notably, dexamethasone prophylaxis at elevated absolute lymphocyte counts post-ciltacabtagene autoleucel (cilta-cel) CAR T-cell therapy significantly reduced atypical neurologic events and improved overall survival, suggesting dexamethasone's immunomodulatory potential extends to managing complications of cellular therapies.

Engineering-focused research increasingly explores dexamethasone-loaded nanoparticle systems to enhance localized delivery and minimize systemic exposure. Formulations spanning multiple delivery modalities—including thermosensitive hydrogels with liposomes for inner ear disease, enzyme-responsive nanoparticles for transmucosal buccal delivery, waterdrop-like microparticles for oral inflammatory bowel disease therapy, and dual-targeted ROS-responsive prodrug liposomes for acute lung injury—demonstrated sustained or triggered release kinetics. In inflammatory bowel disease models, dexamethasone-loaded microparticles achieved superior outcomes compared to free drug administration, manifesting in enhanced weight recovery and improved histopathological scores. Several studies applied dexamethasone-loaded nanoparticles to ocular indications including experimental uveitis, with PHBSA nanoparticles reducing pro-inflammatory cytokines and clinical signs of inflammation comparable to intravitreal implant approaches.

Mechanistic studies identified dexamethasone's biological activities in modulating immune cell populations and tissue remodeling. Machine learning-driven analysis of spinal cord injury identified dexamethasone alongside Atorvastatin as candidate modulators of macrophage polarization through genes associated with immune pathways. In multiple myeloma patients receiving bortezomib-lenalidomide-dexamethasone, the regimen transiently expanded monocytic myeloid-derived suppressor cells that correlated with response depth, though this expansion did not independently predict treatment outcome after adjusting for disease stage. Conversely, an oral probiotic, Limosilactobacillus fermentum ANC4, mitigated dexamethasone-induced muscle atrophy in mice by downregulating glucocorticoid receptor signaling and ubiquitin ligases while preserving myogenic markers, highlighting a potential complementary strategy against glucocorticoid-induced side effects.

Dexamethasone also figured as an adjunctive agent in specialized clinical contexts. Reduced-dose dexamethasone premedication for weekly paclitaxel chemotherapy was evaluated for its capacity to prevent taxane-induced hypersensitivity reactions while lowering steroid-related toxicity. In tuberculous meningitis, pharmacokinetic studies documented dexamethasone exposure kinetics when co-administered with rifampicin, addressing the therapeutic challenge of drug-drug interactions. Comparative efficacy studies between dexamethasone and emerging alternatives—including fluocinolone acetonide intravitreal implants in posterior-segment uveitis, cerium-luteolin nanoparticles in ocular alkali burns, and novel plant-derived compounds in ulcerative colitis—reinforced dexamethasone's benchmark role as a reference standard for anti-inflammatory efficacy and safety profiling across diverse disease models.

Key Publications

• NEWJul Circulating M-MDSC Expansion During Therapy Associates With Treatment Response in Multiple Myeloma: A Longitudinal Observational Study. (Clinical and translational science, 2026, PMID 42374568): "VRd, but not daratumumab-based regimens, significantly expanded M-MDSCs (median +0.98%, p<0.0001), which normalized after ASCT."
• NEWJun Reduced-dose dexamethasone premedication for weekly paclitaxel: a retrospective cohort study of early hypersensitivity reactions and steroid-related toxicity. (Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026, PMID 42371187): "...premedication with dexamethasone; however, prolonged or high-dose exposure to dexamethasone increases the risk of adverse effects."
• NEWJun Coordination-driven self-assembly of antioxidative and anti-inflammatory cerium-luteolin nanoparticles for effective treatment of ocular alkali burns. (Journal of materials chemistry. B, 2026, PMID 42301120): "They outperform the individual components and match the efficacy of dexamethasone, without observable adverse effects."
• NEWJul Bacterial Communities Identified by Standard Culture and 16S rRNA Amplicon Sequencing in Ophthalmic Preservative-Free Dexamethasone SP Used in Canine Cataract Surgery. (Veterinary ophthalmology, 2026, PMID 42290185): "To assess different lots and brands of sterile preservative-free dexamethasone sodium phosphate (dexamethasone SP) for evidence of bacterial contamination via culture-dependent and independent methods, and quantify endotoxin."
• Jun Salivary Enzyme-Responsive Switching Nanoparticles Overcoming Diffusion and Absorption Barriers for Transmucosal Delivery. (ACS applied materials & interfaces, 2026, PMID 42233472): "Furthermore, this switching design does not compromise drug release, maintaining diffusion-dominated sustained release of dexamethasone (DEX)."
• May Engineered microparticle morphology for enhanced intestinal retention in oral drug delivery. (Acta biomaterialia, 2026, PMID 42217660): "In a murine inflammatory bowel disease (IBD) model, dexamethasone (DXM)-loaded WDMPs outperformed conventional free drug administration, manifesting in significantly improved therapeutic outcomes: 1.16-fold enhanced weight recovery, 1.27-fold greater colon length preservation, and superior histopathological scores."
• May Fluocinolone Acetonide Versus Dexamethasone Intravitreal Implants for Non-Infectious Posterior-Segment Uveitis: 12-Month Real-World Outcomes. (Ocular immunology and inflammation, 2026, PMID 42188201): "To compare 12-month real-world outcomes and safety profiles of the fluocinolone acetonide intravitreal implant (FAi) versus the dexamethasone intravitreal implant (DEX) in non-infectious posterior-segment uveitis."
• May Attenuation of LPS-induced inflammatory responses in J774A.1 macrophages by phenylpropanoids and ursane triterpenes from Lavandula coronopifolia Poir. (Scientific reports, 2026, PMID 42178365): "They also altered cell morphology in a manner similar to dexamethasone."
• May Reliability of the Overnight Dexamethasone Suppression Test in Patients Undergoing Bariatric Surgery. (Obesity surgery, 2026, PMID 42176158): "evaluate the reliability of dexamethasone suppression test (DST) in post-bariatric surgery patients"
• May The safety profile of lenalidomide, dexamethasone, daratumumab, and bortezomib combinations in multiple myeloma: a retrospective analysis of the FAERS database. (Naunyn-Schmiedeberg's archives of pharmacology, 2026, PMID 42171749): "The current study aimed to compare the real-world safety profiles of first-line multiple myeloma regimens-lenalidomide plus dexamethasone (Rd), bortezomib plus lenalidomide and dexamethasone (VRd), and daratumumab plus lenalidomide and dexamethasone (DRd)-using the FDA Adverse Event Reporting System (FAERS) database."